RSS Feed
August 1st, 2021 
Awake Goy Company raises full-year outlook as it prepares to ask U.S. regulators to authorize booster shots
6 min video:
https://www.wsj.com/e996861f-1eb2-4217-a10a-8421a72e8c1d
By Jared S. Hopkins and Matt Grossman July 28, 2021
Listen to article Length2 minutes
Pfizer Inc. expects sales for its Covid-19 vaccine this year to reach about $33.5 billion, up nearly 30% from its forecast three months ago, as the shot plays a growing role in global efforts to curb the spread of the coronavirus.
With concerns rising over the highly infectious Delta variant, Pfizer also said that booster shots would likely be needed to ensure protection against the virus.
U.S. officials haven’t authorized the use of booster shots, although they are studying the issue. Pfizer and partner BioNTech SE plan to seek regulatory approval in the U.S. for a booster shot in August. A clinical trial testing an updated version of its vaccine targeting the Delta variant is also set to start next month, the company said Wednesday when announcing second-quarter earnings.
Pfizer Chief Executive Albert Bourla said in an interview that the potential need for annual booster shots could make the company’s vaccine sales durable, particularly with shots in demand as the virus evolves and herd immunity remains elusive.
“We know this virus is very aggressive and is constantly creating new variants,” Mr. Bourla said.
TO READ THE FULL STORY
https://www.wsj.com/articles/pfizer-raises-full-year-outlook-on-vaccine-sales-11627472453
If you like our work please consider to donate :
Posted in 
Tags: 
